Abstract
There are numerous concerns related to treatment choices involving early dopaminergic therapy in Parkinson's disease. These include the effect on the underlying progression of the neurodegenerative process as well as the development of motor complications such as fluctuations and dyskinesias. A number of recent basic and clinical studies have provided new insights but have also added confusion and controversy. This report summarizes presentations and discussion dealing with these issues from a one-day symposium involving Canadian Movement Disorders neurologists.
| Original language | English |
|---|---|
| Pages (from-to) | 277-286 |
| Number of pages | 10 |
| Journal | Canadian Journal of Neurological Sciences |
| Volume | 32 |
| Issue number | 3 |
| DOIs | |
| State | Published - Aug 2005 |